glp-1 treatment New Guidelines on Drugs for Obesity Released GLP-1 Weight Loss - CasaGlow

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk - Full Text View - ClinicalTrials.gov

This study also showed that a global KO of FFA3 results in the downregulation of GLP-1R levels in mouse islets

In the pancreas, it stimulates insulin release, suppressing glucagon secretion during hyperglycemia

People who made dosing errors while administering semaglutide from compounding pharmacies have been harmed and even hospitalized after accidentally taking too much, according to an alert issued last week by the FDA

As a dual agonist, it targets both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

New Interpretation of Oral Glucose Tolerance